Connect with us

Technology

FDA Approves Teal Health’s Teal Wand™–The First and Only At-Home Self-Collection Device for Cervical Cancer Screening, Introducing a Comfortable Alternative to In-Person Screening

Published

on

Women can now collect their own sample from the privacy of home, no speculum required, and mail it to a certified lab to be tested on the same test as the doctor’s office, with the same accuracy.

SAN FRANCISCO, May 9, 2025 /PRNewswire/ — Teal Health®, a women’s health company on a mission to eliminate cervical cancer, today announced the Food and Drug Administration’s (FDA) approval of the Teal Wand™, the first and only at-home vaginal sample self-collection device for cervical cancer screening in the United States. Cervical cancer screenings, commonly referred to as the Pap smear, are critical to a woman’s health, but they are inconvenient and uncomfortable for most. Now women have a new way to screen that is as accurate as going to the doctor’s office, comfortable, and done from home. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged 25–65 at average risk. The at-home screening includes both the Teal Wand collection kit and an end-to-end telehealth service providing virtual access to Teal medical providers who prescribe the kit, review the results from the lab, and support women throughout their at-home screening experience.

Cervical cancer is one of the only cancers that is almost entirely preventable with regular screening, yet more than 1 in 4 women in the U.S. are behind. Whether it’s because a woman can’t get time off work, is unable to find an available appointment, or avoids the discomfort of an in-clinic exam, Teal can provide a comfortable and convenient option. The Teal Wand is a preferred alternative, one that has been built with empathy, is driven by science, and designed to make screening easy, so that more women can take control of their health on their own terms.

“As a mom and a woman, I get how easy it is to put your own health last,” said Kara Egan, CEO and Co-Founder of Teal Health. “That’s why this FDA approval means so much; it’s not just about an innovative new product, it’s about finally giving women an option that makes sense for their lives – something that can be done quickly and comfortably at home. Because when we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day.”

With the Teal Wand, women are testing a sample for HPV (human papillomavirus), the virus that causes nearly all cervical cancers, using the same highly accurate HPV test that medical guidelines recommend and providers use in the clinic – cobas® HPV from Roche. The Teal Wand simply provides a different method of sample collection. Cervical cancer screening has evolved from the Pap smear to HPV primary screening. HPV primary screening demonstrates higher sensitivity compared to the Pap test to identify women who may be at risk of cervical cancer. With this FDA approval, women can use the same test as the doctor’s office, with the same accuracy, but collect their own sample from the privacy of their home, the sample is then conveniently shipped to a certified lab for processing.

Teal Health’s FDA approval was supported by their SELF-CERV study, the largest U.S.-based comparative study of its kind. The study confirmed that self-collected samples using the Teal Wand have the same performance as clinician-collected samples, proven to detect cervical precancer 96% of the time, and that the Teal Wand is a much preferred experience. Study participants reflected the racial, ethnic, and socioeconomic diversity of the U.S. population, underscoring Teal Health’s commitment to clinical excellence, equity, and inclusivity in women’s health research. Notably, 86% of participants said they’d be more likely to stay up to date with cervical cancer screening if they could do it at home, and 94% said they would prefer to self-collect at home with the Teal Wand if they knew it was accurate. The clinical performance and preference for the Teal Wand, alongside Teal’s comprehensive telehealth service, highlight the potential of at-home self-collection to expand access to high-quality cervical cancer screening and improve outcomes.

“As a Principal Investigator in the SELF-CERV trial, I saw firsthand how receptive and excited women were to use the Teal Wand. Cervical cancer is largely preventable, yet screening rates in the U.S. continue to lag, and the FDA approval of this at-home Teal Wand self-collection device is a critical step forward. It offers an evidence-based way to expand access without compromising accuracy.” Said Dr. Christine Conageski, Associate Professor, OB-GYN and Director of the Complex Dysplasia Clinic at the University of Colorado, “But access is only part of the solution. Comprehensive screening must go hand in hand with structured, reliable follow-up. That’s why Teal Health’s approach to not only advancing screening technology but also providing education and support to women through every step of their care and follow-up journey is crucial. That’s how we ensure this breakthrough truly closes the gap.”

With FDA approval in hand, Teal Health is moving quickly to get the Teal Wand to as many women as possible. Kits become available in June, starting in California and expanding nationwide as soon as possible thereafter. Teal is working with major insurance providers and plans to have flexible payment options, helping to remove financial concerns and ensuring more women have access to this preferred at-home screening if they want it.

“The FDA prioritized the review of at-home self-collection, recognizing its potential to increase cervical cancer screening adherence, as emphasized in the recent USPSTF (United States Preventive Services Task Force) draft guidelines,” said Trena Depel, Teal Health’s VP of Clinical, Regulatory, and Quality. “After awarding the Teal Wand Breakthrough Device Designation, the FDA stayed committed to a timely review, leading to approval of a technology that delivers meaningful performance, benefits, and choice. This isn’t just a win for Teal—it’s a win for every woman who deserves a rigorously tested and FDA reviewed at-home cervical cancer screening option.”

The approval of the Teal Wand and the shift toward at-home cervical cancer screening signals a new era in healthcare, one designed around women’s comfort, control, and real-life preferences. Join the waitlist at getteal.com to be the first to know when Teal Health expands to your state. Waitlisters get early access to updates and availability.

About Teal Health
Teal Health is a woman-led company on a mission to improve women’s healthcare experiences – starting with the first FDA-approved at-home cervical cancer screening. By creating the option for a woman to screen for cervical cancer from the comfort of home and providing virtual support along the way, and personalized follow-up when needed, Teal can increase access to this life-saving cancer screening. Teal Health is a member of the Cervical Cancer Roundtable, a joint collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders with the goal of eliminating cervical cancer as a public health concern in the US. To learn more, visit www.getteal.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-teal-healths-teal-wandthe-first-and-only-at-home-self-collection-device-for-cervical-cancer-screening-introducing-a-comfortable-alternative-to-in-person-screening-302451189.html

SOURCE Teal Health

Continue Reading

Technology

The RBC iShares alliance launches ETF Series of RBC QUBE Market Neutral World Equity Fund (CAD Hedged)

Published

on

By

TORONTO, Sept. 24, 2026 /CNW/ — The RBC iShares alliance today announced the launch of ETF Series units of RBC QUBE Market Neutral World Equity Fund (CAD Hedged) (the “ETF Series”), adding to its suite of alternative investment solutions. The new ETF Series is managed by RBC Global Asset Management Inc. (“RBC GAM Inc.”) and is expected to begin trading on Cboe Canada today.

Fund

Ticker Symbol

Management Fee

RBC QUBE Market Neutral World Equity Fund (CAD Hedged) – ETF Series

RNWH

1.00 %

Absolute return strategy designed to seek capital growth independent of market movements
The new ETF Series expands the suite of liquid alternative investment solutions offered by the RBC iShares alliance. RBC QUBE Market Neutral World Equity Fund (CAD Hedged) aims to provide consistent capital growth that is substantially independent of the performance of the global equity market by investing primarily in units of RBC QUBE Market Neutral World Equity Fund (the “Underlying Fund”). The Underlying Fund takes long and short positions primarily in securities that are listed on major global stock exchanges using a quantitative investment model designed to select individual stocks, control portfolio-level risk and maximize exposure to factors associated with outperformance. Additionally, RBC QUBE Market Neutral World Equity Fund (CAD Hedged) seeks to minimize exposure to currency fluctuations between the U.S. dollar and the Canadian dollar by using a hedging strategy.

“Sophisticated investors have long used market neutral strategies to help offset the impact of market volatility on their portfolios,” said Mark Neill, Managing Director and Head of Exchange-Traded Funds and Strategic Alliances, RBC Global Asset Management Inc. “By launching RBC QUBE Market Neutral World Equity Fund (CAD Hedged) in an ETF series, the RBC iShares alliance is expanding its alternative investment solution set to provide Canadian advisors and investors with an institutional style product in a convenient ETF format.”

Capital gains distribution payment method for ETF Series units of RBC QUBE Market Neutral World Equity Fund and RBC QUBE Market Neutral World Equity Fund (CAD Hedged)
RBC GAM Inc. will file an amendment to the RBC Funds simplified prospectus today to clarify that RBC QUBE Market Neutral World Equity Fund and RBC QUBE Market Neutral World Equity Fund (CAD Hedged) intend to distribute any net capital gains for ETF Series units quarterly in March, June, September, and December which, in RBC GAM Inc.’s discretion, may be paid in cash or reinvested automatically in additional ETF Series units of the applicable fund at a price equal to the net asset value per ETF Series unit of the applicable fund. In the case of any reinvestment, the ETF Series units will be immediately consolidated, such that the number of outstanding ETF Series units following the distribution will equal the number of ETF Series units outstanding prior to the distribution.

The RBC iShares alliance aims to help clients achieve their investment objectives by empowering them to build efficient portfolios and take control of their financial futures. The RBC iShares alliance is committed to delivering a truly differentiated ETF experience and positive outcomes for clients.

For more information about RBC QUBE Market Neutral World Equity Fund (CAD Hedged), please visit https://www.rbcgam.com/en/ca/products/alternative-investments/about/.

The RBC iShares alliance includes RBC ETFs and ETF Series of RBC Funds managed by RBC Global Asset Management Inc. (“RBC GAM Inc.”) and iShares ETFs managed by BlackRock Asset Management Canada Limited. Commissions, management fees and expenses all may be associated with investments in exchange-traded funds (“ETFs”). Please read the applicable prospectus or ETF Facts document before investing. ETFs are not guaranteed, their values change frequently, and past performance may not be repeated. ETF Series is a class of securities offered by a conventional mutual fund however, unlike conventional mutual fund series, ETF Series are bought and sold at market price on a stock exchange like an ETF. Brokerage commissions will reduce returns. RBC Funds are managed by RBC Global Asset Management Inc., which is a member of the RBC GAM group of companies and an indirect wholly-owned subsidiary of Royal Bank of Canada.

About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 105,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada’s biggest bank and one of the largest in the world, based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our more than 19 million clients in Canada, the U.S. and 27 other countries. Learn more at rbc.com.‎

We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/peopleandplanet.

About RBC Global Asset Management
RBC Global Asset Management (RBC GAM) is the asset management division of Royal Bank of Canada (RBC). RBC GAM is a provider of global investment management services and solutions to institutional, high-net-worth and individual investors through separate accounts, pooled funds, mutual funds, hedge funds, exchange-traded funds and specialty investment strategies. RBC Funds, BlueBay Funds, PH&N Funds and RBC ETFs are offered by RBC Global Asset Management Inc. (RBC GAM Inc.) and distributed through authorized dealers in Canada. The RBC GAM group of companies, which includes RBC GAM Inc. (including PH&N Institutional), manage approximately $834 billion in assets and have approximately 1,600 employees located across Canada, the United States, Europe and Asia.

About BlackRock 
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs 
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $6.2 trillion in assets under management as of June 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.

For more information, please contact:
Brandon Dorey, RBC GAM Corporate Communications, 647-262-6307

SOURCE RBC Global Asset Management Inc.

Continue Reading

Technology

Kipsu Announces Strategic Investment from M-One Capital to Accelerate Growth and Expansion

Published

on

By

Partnership will provide growth capital and strategic resources to support Kipsu’s continued business and team growth, industry-expansion across hospitality, healthcare and other customer experience-focused markets.

MINNEAPOLIS, Sept. 24, 2026 /PRNewswire/ — Kipsu, Inc. (“Kipsu” or the “Company”), a leading customer experience platform that helps hospitality, healthcare and other service leaders engage customers in real time and coordinate the operational workflows required to deliver exceptional service, today announced a strategic partnership with M-One Capital (“M-One”), a private investment firm. As part of the partnership, M-One has made a minority investment in Kipsu. Terms of the transaction were not disclosed.

Kipsu helps high touch service organizations engage the people they serve and coordinate operational workflows to deliver exceptional service. The Company plans to continue expansion within the hospitality industry, developing additional operational and AI-enabled capabilities, and grow in markets like healthcare where responsive communication and coordinated service execution are increasingly important. The Company will also continue to seek strategic acquisition opportunities that complement its technology and extend the value it provides to customers.

“We built Kipsu with a long-term view of where this market is headed,” said Chris Smith, founder and CEO of Kipsu. “Today we are a satisfaction company helping organizations deliver better experiences in the moments that matter. This partnership gives us more resources to keep building — growing our team, investing in our products and expanding our impact. M-One understands what we’re building and shares our long-term perspective, which made them the right partner for this next stage of growth.”

M-One Capital brings extensive experience partnering with founder-led companies and helping management teams execute long-term growth strategies. The firm was drawn to Kipsu’s guest engagement platform, strong customer retention, culture of innovation and the team’s track record of building and scaling a mission-critical solution for hospitality and other service-focused organizations.

“We are excited to partner with the Kipsu team,” said BJ Hansen, Managing Director at M-One Capital. “Kipsu has built a technology platform in an increasingly important category. The team has demonstrated a consistent ability to execute, deepen customer relationships and expand the Company’s capabilities while maintaining a strong and distinctive culture. We look forward to supporting management as Kipsu invests in product innovation, expands within hospitality and brings its platform to additional markets.”

About Kipsu

Kipsu is a technology platform that provides frontline customer experience solutions to hospitality, healthcare, and other leading service organizations. Kipsu’s software enables customers to improve service delivery through real-time digital engagement and operational execution. The Company’s platform helps organizations strengthen customer communication, coordinate frontline workflows, and deliver more responsive and personalized experiences. Headquartered in Minneapolis, MN, Kipsu serves over 45M guests each year across more than 11,000 sites around the world.

About M-One Capital

M-One Capital Management, LLC is a registered investment adviser that conducts business as M-One Capital. Headquartered in Omaha, Nebraska, M-One Capital is a private investment firm focused on being a value-added partner for management teams, founders, and family owners. Specializing in supporting management teams who retain operating control and meaningful ownership, M-One Capital provides equity capital, guidance, and strategic resources to the entrepreneurs and companies in which it invests. McCarthy Capital rebranded to M-One Capital in 2025. For more information, please visit m-onecapital.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kipsu-announces-strategic-investment-from-m-one-capital-to-accelerate-growth-and-expansion-302888583.html

SOURCE Kipsu

Continue Reading

Technology

Proprioceptive AI Outlines Roadmap for Model Interpretability and Targeted Adaptation

Published

on

By

Operational V1 and internal research underpin the company’s next phase of scientific validation, patent prosecution and commercial development.

PHOENIX, Sept. 24, 2026 /PRNewswire/ — Proprioceptive AI, Inc. is advancing its model interpretability and targeted adaptation technology toward independent scientific evaluation and commercial deployment. Its product strategy centers on probes and adapters for local models and large-scale commercial clients, connecting analysis of internal model states with targeted improvements to model behavior.

Proprioceptive AI advances probes and adapters for model interpretability and targeted adaptation.

The company’s V1 system is operational in a private research environment. In defined internal tests, Proprioceptive AI reported an 85.8% reduction in confident-wrong output. Its internal work includes model-state probes, targeted corrections and capability checks. The next phase builds on these results through independent reproduction, broader evaluation and product development.

Commercial AI teams, developers and researchers: visit www.proprioceptiveai.com and contact Logan@proprioceptiveai.com to discuss model evaluation, targeted adaptation or scientific collaboration.

Proprioceptive AI’s approach links three functions: sensing internal model states, applying targeted interventions and verifying their effects. Its research and intellectual property strategy extends across the interfaces needed to read and influence model states across supported architectures. The objective is to turn internal model insight into practical control over behavior and measurable improvements in model quality.

“We are building technology to understand and shape model behavior from within,” said Logan Napolitano of Proprioceptive AI. “V1 is operational, and our internal research provides the foundation. We are now focused on independent scientific evaluation and delivering probes and adapters that serve both local-model users and commercial AI teams.”

The company is recruiting scientists to expand its research and validation work. The next phase will focus on:

Independent reproduction: Reproduce internal findings using documented protocols and external reviewers.Model quality: Measure targeted performance improvements against baseline models and relevant alternative methods.Capability preservation: Evaluate the effects of interventions on other model capabilities, including regressions and behavior on held-out data.Deployment performance: Establish supported-model coverage, integration requirements, latency and computing costs for customer environments.

This program will connect research results to defined product specifications and customer acceptance criteria. For commercial clients, the company’s planned engagement model progresses from model diagnostics to targeted adaptation and deployment evaluation, with technical scope and performance requirements established for each engagement.

Proprioceptive AI has retained both intellectual property counsel and securities counsel. The company is pursuing patent prosecution and working with Castle Placement on investor preparation as it develops the scientific, legal and commercial foundations for growth.

Its immediate priorities are to expand the scientific team, organize external evaluation and package the technology for repeatable customer testing. The broader ambition is to give developers and organizations the tools to interpret, adapt and improve the models they operate.

About Proprioceptive AI, Inc.

Proprioceptive AI, Inc. develops technology for model interpretability and targeted adaptation. Its work spans internal-state sensing, model-state interfaces, targeted intervention and outcome verification, with a product strategy focused on probes and adapters for local models and commercial AI deployments.

Learn more at www.proprioceptiveai.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/proprioceptive-ai-outlines-roadmap-for-model-interpretability-and-targeted-adaptation-302888783.html

SOURCE Proprioceptive AI, Inc

Continue Reading

Trending